QIAGEN NV

QIAAGEN’s QuantiFERON‑TB Gold Plus proves highly effective for TB screening in immunocompromised and other high‑risk groups, supporting global TB prevention strategies.

QIAGEN NV boosts its single‑cell genomics lineup with Parse Biosciences Evercode V4, expands into Japan’s point‑of‑care market, and navigates industry consolidation while maintaining stable equity performance.

QIAGEN NV gains from a bullish European market: strong fundamentals, expanding diagnostics portfolio, and a positive outlook amid industry consolidation.

Q I A G E N’s Q4 2025 earnings webcast—short interest easing, DAX volatility, and booming life‑science markets—could redefine its 2026 outlook and investor confidence.

Discover how QIAGEN NV’s Sample to Insight solutions drive innovation across diagnostics, pharma, forensics, and food safety, powering a €8.5 bn market cap and solid investor confidence.

Entdecken Sie, warum QIAGEN NV trotz kleiner Marktkapitalisierung im DAX 40 stabile Preise und defensive Wachstumschancen bietet – ein solides Fundament für langfristige Investoren.

QIAGEN NV has acquired Genoox, an AI-powered software provider, to enhance its digital offerings and expand its capabilities in genetic data analysis, positioning the company for growth in the rapidly evolving genomics landscape.

Qiagen NV has announced a strong start to 2025 with plans for a $500 million share buyback and a regular annual dividend, driven by its impressive first-quarter financial performance.